An investigation for investors in NASDAQ:OCRX shares was announced concerning possible violations of securities laws by Ocera Therapeutics and certain of its directors and officers.
Investors who purchased shares of Ocera Therapeutics Inc (NASDAQ:OCRX), have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 – 1554.
The investigation by a law firm focuses on whether certain statements by Ocera Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Palo Alto, CA based Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on acute and chronic orphan liver diseases.
On January 30, 2017, Ocera Therapeutics Inc reported the results of its Phase 2b study of Ornithine Phenylacetate were not statistically significant in terms of the primary and secondary endpoints.
Shares of Ocera Therapeutics Inc (NASDAQ:OCRX) declined to as low as $0.52 per share on February 7, 2017.
Those who purchased NASDAQ:OCRX shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego